183 related articles for article (PubMed ID: 24495481)
1. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.
Ma X; Rousseau V; Sun H; Lantuejoul S; Filipits M; Pirker R; Popper H; Mendiboure J; Vataire AL; Le Chevalier T; Soria JC; Brambilla E; Dunant A; Hainaut P;
Mol Oncol; 2014 May; 8(3):555-64. PubMed ID: 24495481
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
[TBL] [Abstract][Full Text] [Related]
3. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.
Voortman J; Goto A; Mendiboure J; Sohn JJ; Schetter AJ; Saito M; Dunant A; Pham TC; Petrini I; Lee A; Khan MA; Hainaut P; Pignon JP; Brambilla E; Popper HH; Filipits M; Harris CC; Giaccone G
Cancer Res; 2010 Nov; 70(21):8288-98. PubMed ID: 20978195
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
[TBL] [Abstract][Full Text] [Related]
6. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
[TBL] [Abstract][Full Text] [Related]
7. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
8. Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.
Graziano SL; Lacas B; Vollmer R; Kratzke R; Popper H; Filipits M; Seymour L; Shepherd FA; Rosell R; Veillard AS; Taron M; Pignon JP
Lung Cancer; 2013 Oct; 82(1):149-55. PubMed ID: 23920379
[TBL] [Abstract][Full Text] [Related]
9. [The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer].
Hirai Y; Shimizu Y; Oura S; Yoshimasu T; Ota F; Nakamura R; Naito K; Nishiguchi H; Hashimoto S; Okamura Y
Gan To Kagaku Ryoho; 2012 Mar; 39(3):381-4. PubMed ID: 22421763
[TBL] [Abstract][Full Text] [Related]
10. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
11. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
12. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
Devarakonda S; Rotolo F; Tsao MS; Lanc I; Brambilla E; Masood A; Olaussen KA; Fulton R; Sakashita S; McLeer-Florin A; Ding K; Le Teuff G; Shepherd FA; Pignon JP; Graziano SL; Kratzke R; Soria JC; Seymour L; Govindan R; Michiels S
J Clin Oncol; 2018 Oct; 36(30):2995-3006. PubMed ID: 30106638
[TBL] [Abstract][Full Text] [Related]
15. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
Ikeda N; Nagase S; Ohira T
Ann Thorac Cardiovasc Surg; 2009 Jun; 15(3):144-9. PubMed ID: 19597387
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
Tsao MS; Aviel-Ronen S; Ding K; Lau D; Liu N; Sakurada A; Whitehead M; Zhu CQ; Livingston R; Johnson DH; Rigas J; Seymour L; Winton T; Shepherd FA
J Clin Oncol; 2007 Nov; 25(33):5240-7. PubMed ID: 18024870
[TBL] [Abstract][Full Text] [Related]
17. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon JP; Tribodet H; Scagliotti GV; Douillard JY; Shepherd FA; Stephens RJ; Dunant A; Torri V; Rosell R; Seymour L; Spiro SG; Rolland E; Fossati R; Aubert D; Ding K; Waller D; Le Chevalier T;
J Clin Oncol; 2008 Jul; 26(21):3552-9. PubMed ID: 18506026
[TBL] [Abstract][Full Text] [Related]
18. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
[TBL] [Abstract][Full Text] [Related]
20. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
